MORDOR II Burkina Faso: Longitudinal Trial

Plain-language summary

This study compares the effects of the antibiotic Azithromycin with placebo in children. Children between 8 days and 59 months of age, with no known allergy to macrolide antibiotics and able to feed orally, may take part. The study was conducted in Phase 4 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 4

Status

Completed

Sponsor

University of California, San Francisco

Intervention

Azithromycin, Placebo

Start date

10/10/2019

Estimated completion

7/6/2020

Countries

Burkina Faso

Related genes

Locations

• Nouna, Burkina Faso

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Between 8 days and 59 months old
* Primary residence within catchment area of study site
* Available for full 6 month study
* No known allergy to macrolides/azalides
* Appropriate written informed consent from at least one parent or guardian
* Able to feed orally

Exclusion Criteria:

* \<8 days old or \>59 months
* Primary residence outside catchment area of study site
* Not available for full 6 month study
* Known allergy to macrolides/azalides
* No written informed consent from at least one parent or guardian
* Unable to feed orally